PURPOSE: Racial disparity in breast cancer outcomes exists between African American and Caucasian women in the United States. We have evaluated the impact of genetically determined ancestry on disparity in efficacy and therapy-induced toxicity for breast cancer patients in the context of a randomized, phase III adjuvant trial. PATIENTS AND METHODS: This study compared outcomes between 386 patients of African ancestry (AA) and 2473 patients of European ancestry (EA) in a randomized, phase III breast cancer trial; ECOG-ACRIN-E5103. The primary efficacy endpoint, invasive disease free survival (DFS) and clinically significant toxicities were compared including: anthracycline-induced congestive heart failure (CHF), taxane-induced peripheral neuropathy (TIPN), and bevacizumab-induced hypertension. RESULTS: Overall, AAs had significantly inferior DFS (p=0.002; HR=1.5) compared with EAs. This was significant in the estrogen receptor-positive subgroup (p=0.03); with a similar, non-significant trend for those who had triple negative breast cancer (TNBC; p=0.12). AAs also had significantly more grade 3-4 TIPN (OR=2.9; p=2.4 ×10-11) and grade 3-4 bevacizumab-induced hypertension (OR=1.6; p=0.02), with a trend for more CHF (OR=1.8; p=0.08). AAs had significantly more dose reductions for paclitaxel (p=6.6 ×10-6). In AAs, dose reductions in paclitaxel had a significant negative impact on DFS (p=0.03); whereas in EAs, dose reductions did not impact outcome (p=0.35). CONCLUSION: AAs had inferior DFS with more clinically important toxicities in ECOG-ACRIN-E5103. The altered risk to benefit ratio for adjuvant breast cancer chemotherapy should lead to additional research with the focus centered on the impact of genetic ancestry on both efficacy and toxicity. Strategies to minimize dose reductions for paclitaxel, especially due to TIPN, are warranted for this population.
PURPOSE: Racial disparity in breast cancer outcomes exists between African American and Caucasian women in the United States. We have evaluated the impact of genetically determined ancestry on disparity in efficacy and therapy-induced toxicity for breast cancer patients in the context of a randomized, phase III adjuvant trial. PATIENTS AND METHODS: This study compared outcomes between 386 patients of African ancestry (AA) and 2473 patients of European ancestry (EA) in a randomized, phase III breast cancer trial; ECOG-ACRIN-E5103. The primary efficacy endpoint, invasive disease free survival (DFS) and clinically significant toxicities were compared including: anthracycline-induced congestive heart failure (CHF), taxane-induced peripheral neuropathy (TIPN), and bevacizumab-induced hypertension. RESULTS: Overall, AAs had significantly inferior DFS (p=0.002; HR=1.5) compared with EAs. This was significant in the estrogen receptor-positive subgroup (p=0.03); with a similar, non-significant trend for those who had triple negative breast cancer (TNBC; p=0.12). AAs also had significantly more grade 3-4 TIPN (OR=2.9; p=2.4 ×10-11) and grade 3-4 bevacizumab-induced hypertension (OR=1.6; p=0.02), with a trend for more CHF (OR=1.8; p=0.08). AAs had significantly more dose reductions for paclitaxel (p=6.6 ×10-6). In AAs, dose reductions in paclitaxel had a significant negative impact on DFS (p=0.03); whereas in EAs, dose reductions did not impact outcome (p=0.35). CONCLUSION: AAs had inferior DFS with more clinically important toxicities in ECOG-ACRIN-E5103. The altered risk to benefit ratio for adjuvant breast cancer chemotherapy should lead to additional research with the focus centered on the impact of genetic ancestry on both efficacy and toxicity. Strategies to minimize dose reductions for paclitaxel, especially due to TIPN, are warranted for this population.
Entities:
Keywords:
DFS; breast cancer; disparity; genetic ancestry; race; toxicity
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Joseph A Sparano; Molin Wang; Fengmin Zhao; Vered Stearns; Silvana Martino; Jennifer A Ligibel; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson Journal: J Natl Cancer Inst Date: 2012-01-16 Impact factor: 13.506
Authors: Roman Kosoy; Rami Nassir; Chao Tian; Phoebe A White; Lesley M Butler; Gabriel Silva; Rick Kittles; Marta E Alarcon-Riquelme; Peter K Gregersen; John W Belmont; Francisco M De La Vega; Michael F Seldin Journal: Hum Mutat Date: 2009-01 Impact factor: 4.878
Authors: D Brock Hewitt; Yaming Li; Oindrila Bhattacharyya; James L Fisher; Daniel Stover; Samilia Obeng-Gyasi Journal: J Racial Ethn Health Disparities Date: 2022-04-06
Authors: Kathryn J Ruddy; Jennifer Le-Rademacher; Mario E Lacouture; Mary Wilkinson; Adedayo A Onitilo; Amy C Vander Woude; Maria T Grosse-Perdekamp; Travis Dockter; Angelina D Tan; Andreas Beutler; Charles L Loprinzi Journal: Breast Date: 2019-09-19 Impact factor: 4.380
Authors: Edward H Ip; Santiago Saldana; Kathy D Miller; Ruth C Carlos; Ilana F Gareen; Joseph A Sparano; Noah Graham; Fengmin Zhao; Ju-Whei Lee; Nathaniel S O'Connell; David Cella; John D Peipert; Robert J Gray; Lynne I Wagner Journal: Cancer Date: 2021-11-02 Impact factor: 6.860
Authors: Gina Kim; Jessica M Pastoriza; John S Condeelis; Joseph A Sparano; Panagiota S Filippou; George S Karagiannis; Maja H Oktay Journal: Front Oncol Date: 2020-06-30 Impact factor: 6.244
Authors: Tarah J Ballinger; Guanglong Jiang; Fei Shen; Kathy D Miller; George W Sledge; Bryan P Schneider Journal: Cancer Date: 2022-03-14 Impact factor: 6.921
Authors: Kathy S Albain; Robert J Gray; Della F Makower; Amir Faghih; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; William C Wood; Maccon M Keane; Henry L Gomez; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge; Joseph A Sparano Journal: J Natl Cancer Inst Date: 2021-04-06 Impact factor: 11.816